Vtv Therapeutics (VTVT) Stock
Clinical stage biotech developing oral drugs for metabolic diseases. Here's the price, business snapshot, and what's worth knowing about Vtv Therapeutics in November 2026.
vTv Therapeutics Inc (VTVT) is a small-cap biotech focused on developing orally delivered small-molecule therapies, historically centred on metabolic and neurological indications. As a clinical-stage company with a market capitalisation around $67 million, it typically has limited or no commercial revenue and is dependent on clinical trial progress, regulatory decisions and potential partnerships to create value. Investors should expect higher-than-average volatility: positive trial results or new licensing agreements can lift the stock, while setbacks, delays or financing needs can depress it. Key items to watch are trial readouts, regulatory updates, cash runway and any collaboration or licensing deals. Given its size, the company may need to raise capital periodically, which could dilute existing shareholders. This summary is for educational purposes only and not personal investment advice; investing in small biotechs carries material risk and investors may wish to seek independent financial advice.
Vtv Therapeutics (VTVT) Stock Forecast
Analyst price target, next 12 months
$52.33
+107.9% vs today's $25.17
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Vtv Therapeutics have a consensus 12-month target of $52.33, above the current price of $25.17.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 28 Aug 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying VTV Therapeutics stock, with a target price indicating significant potential growth.
Financial Health
VTV Therapeutics is showing strong revenue and cash flow, indicating solid financial performance.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Clinical-stage catalysts
Trial readouts and regulatory milestones can create sharp share-price moves, though outcomes are uncertain and may disappoint.
Pipeline and focus
The company focuses on small-molecule therapies in metabolic and neurological areas, offering potential upside alongside typical clinical-stage risk.
Capital and partners
Watch cash runway and any licensing or partnership activity, since raising funds could dilute holders while deals can de‑risk programmes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
